The company has substantially boosted the development of the innovative therapy for ATTR-CM, leveraging Attruby. Initial clinical information suggests potential benefits for patients suffering by the serious disease. The focus represents the company’s commitment to treating significant healthcare demands in the heart space. Attruby: BridgeBio's